Haemonetics (NYSE:HAE) Stock Rating Reaffirmed by Barrington Research

Haemonetics (NYSE:HAE)‘s stock had its “outperform” rating reiterated by analysts at Barrington Research in a research note issued to investors on Friday, Benzinga reports. They presently have a $105.00 target price on the medical instruments supplier’s stock. Barrington Research’s target price would indicate a potential upside of 23.21% from the company’s previous close. Barrington Research also issued estimates for Haemonetics’ FY2026 earnings at $4.80 EPS and FY2027 earnings at $5.52 EPS.

Several other analysts have also issued reports on HAE. StockNews.com lowered Haemonetics from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. TheStreet lowered Haemonetics from a “b-” rating to a “c+” rating in a report on Thursday, February 29th.

Haemonetics Stock Down 1.5 %

Haemonetics stock opened at $85.22 on Friday. The stock has a market cap of $4.33 billion, a PE ratio of 34.64, a price-to-earnings-growth ratio of 2.04 and a beta of 0.36. The company has a debt-to-equity ratio of 0.91, a quick ratio of 1.76 and a current ratio of 2.92. Haemonetics has a one year low of $70.74 and a one year high of $95.26. The stock has a fifty day moving average of $78.23 and a 200 day moving average of $82.87.

Haemonetics (NYSE:HAE) last posted its quarterly earnings data on Thursday, February 8th. The medical instruments supplier reported $1.04 EPS for the quarter, beating analysts’ consensus estimates of $0.94 by $0.10. The company had revenue of $336.20 million during the quarter, compared to analysts’ expectations of $320.84 million. Haemonetics had a return on equity of 22.37% and a net margin of 9.97%. Haemonetics’s revenue for the quarter was up 10.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.85 earnings per share. As a group, sell-side analysts predict that Haemonetics will post 3.95 EPS for the current year.

Institutional Trading of Haemonetics

Hedge funds have recently bought and sold shares of the stock. Stifel Financial Corp boosted its stake in shares of Haemonetics by 2.5% in the first quarter. Stifel Financial Corp now owns 4,891 shares of the medical instruments supplier’s stock worth $405,000 after acquiring an additional 119 shares during the period. Knights of Columbus Asset Advisors LLC boosted its stake in shares of Haemonetics by 1.3% in the third quarter. Knights of Columbus Asset Advisors LLC now owns 10,005 shares of the medical instruments supplier’s stock worth $896,000 after acquiring an additional 128 shares during the period. Meeder Asset Management Inc. boosted its stake in shares of Haemonetics by 65.2% in the fourth quarter. Meeder Asset Management Inc. now owns 342 shares of the medical instruments supplier’s stock worth $27,000 after acquiring an additional 135 shares during the period. Metropolitan Life Insurance Co NY boosted its stake in shares of Haemonetics by 4.5% in the fourth quarter. Metropolitan Life Insurance Co NY now owns 3,202 shares of the medical instruments supplier’s stock worth $252,000 after acquiring an additional 138 shares during the period. Finally, Parkside Financial Bank & Trust boosted its stake in shares of Haemonetics by 21.7% in the second quarter. Parkside Financial Bank & Trust now owns 786 shares of the medical instruments supplier’s stock worth $67,000 after acquiring an additional 140 shares during the period. Institutional investors own 99.67% of the company’s stock.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360.